This review highlights that despite advances in primary interventions and pharmacological therapies, effective treatments specifically targeting left ventricular remodelling after myocardial infarction remain inadequate.
No takes yet. Share an insight, caveat, or question.
LV remodelling therapy remains inadequate post-MI; leaves open identification of effective novel targets beyond current agents and gene therapy.
Cokkinos et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: